Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Simple Search

Search Type: Criteria:

You could also try: mistake (35), fault (22), slip (31)

Pertuzumab/Trastuzumab SC

Description: Chemotherapy Protocol BREAST CANCER Regimen Pertuzumab / Trastuzumab SC • Breast Cancer – Trastuzumab / Pertuzumab SC Indication • Treatment of early breast cancer (EBC) in
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/PertuzumabTrastuzumab-SC.pdf

HSCTMelphalan-Bortezomib IV

Description: Chemotherapy Protocol HAEMATOLOGY – HSCT AUTOGRAFT InP - MELPHALAN and BORTEZOMIB (IV) Please confirm correct protocol with transplant schedule Regimen • HSCT – InP - Melphalan
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Transplant/HSCTMelphalan-Bortezomib-IV.pdf

HSCTMelphalan 200mg/m²

Description: Chemotherapy Protocol HAEMATOLOGY – HSCT AUTOGRAFT MELPHALAN (200mg/m2) Multiple Myeloma This regimen will only be available to prescribe at units which
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Transplant/HSCTMelphalan-200mg-m².pdf

HSCTCyclophosphamideTBI_Related_Methotrexate_GvHD

Description: Chemotherapy Protocol HAEMATOLOGY – HSCT ALLOGRAFT CYCLOPHOSPHAMIDE-TOTAL BODY IRRADIATION (TBI)-METHOTREXATE (GvHD) Related Donor Conditioning This regimen will only be available
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Transplant/HSCTCyclophosphamideTBI-Related-Methotrexate-GvHD.pdf

HSCTAlemtuzumabCyclophosphamideTBI_VUD_Methotrexate_GvHD

Description: Chemotherapy Protocol HAEMATOLOGY – HSCT ALLOGRAFT ALEMTUZUMAB-CYCLOPHOSPHAMIDE-TOTAL BODY IRRADIATION (TBI)METHOTREXATE (GvHD) Volunteer Unrelated Donor (VUD) Conditioning This regimen will
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Transplant/HSCTAlemtuzumabCyclophosphamideTBI-VUD-Methotrexate-GvHD.pdf

VR-RituximabVenetoclax Cycle_2 Onwards

Description: Chemotherapy Protocol Chronic Lymphocytic Leukaemia VR-RITUXIMAB-VENETOCLAX (high risk) (Cycle 2 onwards) Regimen • CLL – VR Rituximab Venetoclax (high risk) Cycle
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/VR-RituximabVenetoclax-Cycle-2-Onwards.pdf

VenetoclaxLow

Description: Chemotherapy Protocol Chronic Lymphocytic Leukaemia VENETOCLAX (low risk) Funding may be required for this regimen. Regimen • CLL – Venetoclax (low risk) Indication
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/VenetoclaxLow.pdf

RFC_PO

Description: Chemotherapy Protocol CHRONIC LYMPHOCYTIC LEUKAEMIA RFC-CYCLOPHOSPHAMIDE-FLUDARABINE-RITUXIMAB (PO) Regimen • CLL – RFC (PO)-Cyclophosphamide-Fludarabine-Rituximab (PO) Indication • Chronic Lymphocytic
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/RFC-PO.pdf

RFC_PO_Split

Description: Chemotherapy Protocol CHRONIC LYMPHOCYTIC LEUKAEMIA CYCLOPHOSPHAMIDE-FLUDARABINE-RITUXIMAB (PO-Split) Regimen • CLL – RFC (PO)-Cyclophosphamide-Fludarabine-Rituximab (PO-Split) Indication • Chronic
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/RFC-PO-Split.pdf

RFC_IV

Description: Chemotherapy Protocol CHRONIC LYMPHOCYTIC LEUKAEMIA CYCLOPHOSPHAMIDE-FLUDARABINE-RITUXIMAB (IV) Regimen • CLL – RFC (IV)-Cyclophosphamide-Fludarabine-Rituximab (IV) Indication • Chronic Lymphocytic Leukaemia
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/RFC-IV.pdf

511 to 520 of 630

Previous … 50 51 52 53 54 … Next